FY2027 EPS Estimate for Telix Pharmaceuticals Cut by Analyst

Key Points

• Analysts at William Blair have reduced their FY2027 EPS estimate for Telix Pharmaceuticals from $0.58 to $0.49, maintaining an "Outperform" rating.
• The consensus estimate for Telix Pharmaceuticals' current full-year earnings stands at $0.24 per share, with several analysts still rating the stock as a Buy.
• Telix Pharmaceuticals opened at $12.48 and has seen institutional investments increasing, with new stakes acquired worth between $170,000 and $451,000.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Analysts at William Blair cut their FY2027 EPS estimates for Telix Pharmaceuticals in a note issued to investors on Thursday, August 21st. William Blair analyst A. Hsieh now anticipates that the company will post earnings per share of $0.49 for the year, down from their previous forecast of $0.58. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share.

Several other research analysts also recently weighed in on TLX. Wedbush reissued an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. HC Wainwright started coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $22.33.

Telix Pharmaceuticals Stock Up 3.2%

Telix Pharmaceuticals stock opened at $12.48 on Monday. The firm's 50 day simple moving average is $14.47 and its 200-day simple moving average is $16.25. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66. Telix Pharmaceuticals has a fifty-two week low of $10.50 and a fifty-two week high of $30.36.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Private Advisor Group LLC acquired a new stake in shares of Telix Pharmaceuticals during the first quarter worth approximately $170,000. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $297,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals during the first quarter worth approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.